Buhl, Anna Sofie Kappel http://orcid.org/0000-0002-4997-2914
Christensen, Troels Dreier
Christensen, Ib Jarle
Nelausen, Knud Mejer
Balslev, Eva
Knoop, Ann Søegaard
Brix, Eva Harder
Svensson, Else
Glavicic, Vesna
Luczak, Adam
Langkjer, Sven Tyge
Linnet, Søren
Jakobsen, Erik Hugger
Bogovic, Jurij
Ejlertsen, Bent
Rasmussen, Annie
Hansen, Anker
Knudsen, Steen
Nielsen, Dorte
Jensen, Peter Buhl
Funding for this research was provided by:
Kræftens Bekæmpelse (R141-A8989-15-S7)
Article History
Received: 29 April 2018
Accepted: 6 August 2018
First Online: 11 August 2018
Compliance with ethical standards
:
: ASKB, AR, AH, SK, and PBJ declare current employment within Medical Prognosis Institute. ASKB, AR, AH, SK, and PBJ declare ownership interest in Medical Prognosis Institute. IJC declares salary from Medical Prognosis Institute. Medical Prognosis Institute holds a patent on the epirubicin DRP. All remaining authors have declared no conflicts of interest.
: All procedures performed in the study involving human participants were in accordance with the ethical standards of The Regional Committee on Health Research Ethics (HGH-2016-097) in Denmark and with the 1964 Helsinki declaration and its later amendments.
: Informed consent was obtained from all individual participants included in the study.